Clinician perspective on molecular profiling of non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 34, Issue 8, 2016, Pages 884-885

  Decatris, Marios P ^a   Farrugia, David ^a   O'Byrne, Kenneth J ^b  

^a Gloucestershire Oncology Centre   (United Kingdom)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ERLOTINIB; GEFITINIB; TUMOR MARKER;

ADVANCED CANCER; BIOINFORMATICS; CANCER THERAPY; HUMAN; LETTER; MUTATION RATE; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; PERSONALIZED MEDICINE; PRIORITY JOURNAL; SOMATIC MUTATION; CLINICAL TRIAL (TOPIC); FEMALE; GENETIC SCREENING; GENETICS; GENOTYPE; MALE; MUTATION; NEOPLASM; PATIENT SELECTION;

BIOMARKERS, TUMOR; CLINICAL TRIALS AS TOPIC; FEMALE; GENETIC TESTING; GENOTYPE; HUMANS; MALE; MUTATION; NEOPLASMS; PATIENT SELECTION;

EID: 84961149047     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.65.2040     Document Type: Letter

References (19)

1. Meric-Bernstam F, Brusco L, Shaw K, et al: Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials. J Clin Oncol 33:2753-2762, 2015
2. Hyamn DM, Solit DB: Tumor genetic screening programmes: A call to action. J Clin Oncol 33:2275-2276, 2015
3. ClinicalTrialgs.gov: Lung-MAP: S1400 biomarker-targeted second-line therapy in treating patient patients with recurrent stage III-IV squamous cell lung cancer. https://clinicaltrials.gov/ct2/show/NCT02154490
4. ClinicalTrials.gov: Intergroup trial UNICANCER UC 0105-1305/ifct1301: Efficacy of targeted drugs guided by genomic profiles in metastatic NSCLC patients (SAFIR02-Lung). https://clinicaltrials.gov/ct2/show/NCT02117167
5. UK Clinical Research Network: National Lung Matrix: Multi-drug phase II trial in NSC lung cancer. http://public.ukcrn.org.uk/Search/StudyDetail.aspx?StudyID517746
6. ClinicalTrials.gov: SPECTAlung: Screening patients with thoracic tumors for efficient clinical trial access. https://clinicaltrials.gov/ct2/show/NCT02214134
7. Schwaderle M, Zhao M, Jack Lee J, et al: Impact of precision medicine in diverse cancers: A meta-analysis of phase II clinical trials. J Clin Oncol 33:3817-3825, 2015
8. Kopetz S, Desai J, Chan E, et al: PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J Clin Oncol 28:269s, 2010 (abstr 3534)
9. Chaft JE, Arcila ME, Paik PK, et al: Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. Mol Cancer Ther 11:485-491, 2012
10. Ginsburg GS, Kuderer NM: Comparative effectiveness research, genomics-enabled personalized medicine, and rapid learning health care: A common bond. J Clin Oncol 30:4233-4242, 2012
11. Johnson FM, Bekele BN, Feng L, et al: Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 28:4609-4615, 2010
12. Swain SM, Baselga J, Kim S-B, et al; CLEOPATRA Study Group: Pertu-zumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372:724-734, 2015
13. Gullapalii RR, Desai KV, Santana-Santos L, et al: Next generation sequencing in clinical medicine: Challenges and lessons for pathology and biomedical informatics. J Pathol Inform 3:40, 2012
14. Pao W, Miller VA: Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: Current knowledge and future directions. J Clin Oncol 23:2556-2568, 2005
15. Oxnard GR, Binder A, Jänne PA: New targetable oncogenes in non-small-cell lung cancer. J Clin Oncol 31:1097-1104, 2013
16. Baselga J: Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: How do we go from INTACT to impact? J Clin Oncol 22: 759-761, 2004
17. Gandara DR, Gumerlock PH: Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: Case closed or is the jury still out? J Clin Oncol 23:5856-5858, 2005
18. Gagan J, Van Allen EM: Next-generation sequencing to guide cancer therapy. Genome Med 7:80, 2015
19. Mendelsohn J: Personalizing oncology: Perspectives and prospects. J Clin Oncol 31:1904-1911, 2013